君實生物-B(1877.HK)收漲8.91%再創上市新高價
格隆匯5月18日丨港股市場生物科技股今日全線大漲,其中,君實生物-B(1877.HK)盤中創上市新高價43.85港元,最終收漲8.91%報42.8港元,成交7744萬港元,最新總市值336億港元。該股自2月初上漲至今,期間最大漲幅達92%。高瓴資本目前持有君實生物-B。有消息稱,高瓴正進行高瓴5期美元基金的募集,目標規模高達130億美元(摺合人民幣約923億元)。相關人士表示,上述募集資金中,100億美元將投入到併購領域,30億美元將分配給成長型投資和風險投資。而且,將主要瞄準疫情之下出現的新機會,尤其是中國市場的機會。接近高瓴的市場人士稱,生物醫藥和醫療器械領域一直是高瓴的重點投資方向,預期未來高瓴還會繼續佈局。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.